Oncology_Logotype-site-1Oncology_Logotype-site-1Oncology_Logotype-site-1Oncology_Logotype-site-1
  • Main
  • Сlinical Trials
    • Completed phase I/IIa clinical trial
    • Case studies
    • Ex-US Clinical Trials
    • US clinical trials
  • Dogs & Cats
    • Comparative Medicine and Veterinary Research
  • Elenagen
    • Elenagen is a Plasmid (Circular DNA) Encoding Gene P62/SQSTM1
    • Elenagen Reduces/Reverts Tumor Grade
    • Elenagen Changes Tumor Microenvironment
    • Elenagen Downregulates Chronic Inflammation
    • Elenagen Enhances Anti-Tumoral Immune Response
  • IP
  • Publications
  • Investors
    • One-pager
    • Slide presentation
  • Team
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
    • Careers
  • News
    • Company news
    • In the news
  • Legal
  • Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors
  • Response of a chemo-resistant triple-negative breast cancer patient to a combination of p62-encoding plasmid, Elenagen, and CMF chemotherapy
  • P62-DNA-encoding plasmid reverts tumor grade, changes tumor stroma, and enhances anticancer immunity
  • Broad-spectrum Anti-tumor and Anti-metastatic DNA Vaccine based on p62-encoding Vector
  • Pilot Study of p62 DNA Vaccine in Dogs with Mammary Tumors
  • P62/SQSTM1 enhances osteogenesis and attenuates inflammatory signals in bone marrow microenvironment
  • Plasmid DNA-coding p62 as a Bone Effective Anti-inflammatory/Anabolic Agent
  • P62 plasmid can alleviate diet-induced obesity and metabolic dysfunctions
  • p62 /SQSTM1 coding plasmid prevents age related macular degeneration in a rat model
  • p62 / SQSTM1 Expression In Canine Mammary Tumours: Evolutionary Notes
  • Neuroprotective effects of p62(SQSTM1)-engineered lactic acid bacteria in Alzheimer’s disease: a pre-clinical study
  • P62/SQSTM1 beyond Autophagy: Physiological Role and Therapeutic Applications in Laboratory and Domestic Animals

Our Manuscripts

Corporate Mission

CureLab Oncology is a biotechnology company that is developing new anti-cancer biologics.
CureLab Oncology is committed to creating a family of revolutionary
therapies for oncology patients in order to help prolong their lives.

Our Lead Product

Our lead product, Elenagen, is a plasmid (supercoiled circular DNA) encoding gene p62/SQSTM1. Elenagen reverses tumor grade, changes tumor microenvironment, enhances the anti-cancer effects of other therapies (e.g. chemotherapy), mitigates chronic inflammation, and stimulates an immune attack on the tumor.

Clinical Trials

  • The CureLab Oncology team has completed its international Phase I/IIa Clinical Trials of Elenagen.
  • The vaccine demonstrated a high degree of safety as well as clinical benefits in a number of patients.
  • We are now preparing Phase II Clinical Trials within the US.

Contact us

E-mail:

info@curelab.com,

Call us:

1-609-841-1201

177 HUNTINGTON
AVE FL 17
BOSTON MA 02115-3156
© 2020 CureLab Oncology.